Opko Health Inc(OPK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:27 AM ET (Korea 10/30 20:27)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.1 | Insider Own | 48.59% | Shs Outstand | 746.0M | Perf Week | 1.84% |
| Market Cap | 1.24B | Forward P/E | - | EPS next Y | -34.56% | Insider Trans | - | Shs Float | 383.7M | Perf Month | 3.11% |
| Enterprise Value | 1.34B | PEG | - | EPS next Q | -0.07 | Inst Own | 28.91% | Short Float | 8.86% | Perf Quarter | 25.76% |
| Income | -0.07B | P/S | 2.11 | EPS this Y | 24.44% | Inst Trans | 1.38% | Short Ratio | 9.21 | Perf Half Y | 47.56% |
| Sales | 0.59B | P/B | 1.05 | EPS next 5Y | 6.53% | ROA | -3.83% | Short Interest | 34.01M | Perf YTD | 31.75% |
| Book/sh | 1.59 | P/C | 4.12 | EPS past 3/5Y | 13.03% - | ROE | -5.88% | 52W High | -6.21% ($1.77) | Perf Year | 16.08% |
| Cash/sh | 0.4 | P/FCF | - | Sales past 3/5Y | -15.45% -15.82% | ROIC | -4.67% | 52W Low | 69.93% ($0.98) | Perf 3Y | 34.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 58.54% | Gross Margin | 27.75% | Volatility(W/M) | 3.31% 5.47% | Perf 5Y | -56.2% |
| Dividend TTM | - | EV/Sales | 2.27 | Sales Y/Y TTM | -11.46% | Oper. Margin | -28.56% | ATR (14) | 0.08 | Perf 10Y | -82.45% |
| Dividend Ex-Date | - | Quick Ratio | 2.93 | EPS Q/Q | 94.11% | Profit Margin | -12.4% | RSI (14) | 58.85 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.35 | Sales Q/Q | 4.32% | SMA20 | 8.53% ($1.53) | Beta | 1.53 | Target Price | $4.15 |
| Payout | - | Debt/Eq | 0.34 | Earnings | 2026/11/4 | SMA50 | 6.45% ($1.56) | Rel Volume | 0.54 | Prev Close | $1.62 |
| Employees | 2275 | LT Debt/Eq | 0.32 | EPS/Sales Surpr. | 87.5% 24.59% | SMA200 | 23.7% ($1.34) | Avg Volume(3M) | 3.69M | Price | $1.66 |
| IPO | 1995/11/2 | Option/Short | Yes/Yes | Trades | 7555 | Volume | 1,976,742 | Change | 2.47% |
🧬 OPKO Health (OPK) is a diversified U.S. healthcare company that operates both diagnostics and pharmaceuticals. Its diagnostics segment, through its subsidiary BioReference Health, offers urology- and oncology-focused tests (4Kscore, GenPath), while its pharmaceutical segment is anchored by Rayaldee, a treatment for chronic kidney disease, and NGENLA (somatrogon), a pediatric growth hormone. The company is distinguished by its business model that combines diagnostics with novel drug development.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 54% of its average volume.
Next earnings report: November 4
5 days to go.
OPK has a sound balance sheet but weak earning power
Of every $100 in sales, $28.56 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +24.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $211. Peers typically go for $458.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -56.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #29 of 44 in the industry
Based on market cap of $1B.
WGS#26 GeneDx Holdings Corp $2B PER - 
PSNL#27 Personalis Inc $2B PER - 
FRNM#28 Freenome Inc $1B PER - OPK#29 Opko Health Inc $1B PER - 
CSTL#30 Castle Biosciences Inc $1B PER - 
FAQ
What kind of company is OPK?
OPK belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of OPK?
The market cap of OPK is approximately $1.2B, ranking 2,438 within its sector.
What is the 52-week high and low for OPK?
OPK has recorded a 52-week high of $1.77 and a low of $0.98.
